Ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":847489142,"tweetId":"847489142","gmtCreate":1636545171919,"gmtModify":1636545172056,"author":{"id":3575056939798485,"idStr":"3575056939798485","authorId":3575056939798485,"authorIdStr":"3575056939798485","name":"Joby","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Ok</body></html>","htmlText":"<html><head></head><body>Ok</body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/847489142","repostId":1121872926,"repostType":4,"repost":{"id":"1121872926","kind":"news","pubTimestamp":1636543098,"share":"https://www.laohu8.com/m/news/1121872926?lang=zh_CN&edition=full","pubTime":"2021-11-10 19:18","market":"us","language":"en","title":"Roche executive says Alzheimer's drug price will be competitive<blockquote>罗氏高管表示阿尔茨海默病药物价格将具有竞争力</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1121872926","media":"Reuters","summary":"Nov 10 (Reuters) - Roche Holding AG, still months away from seeking regulatory approval of its exper","content":"Nov 10 (Reuters) - Roche Holding AG, still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival Biogen Inc's Aduhelm, saying that its medication would be priced competitively.<blockquote>路透11月10日-罗氏控股公司距离其实验性阿尔茨海默病药物获得监管部门批准还有几个月的时间，该公司已经将目标瞄准了竞争对手百健公司(Biogen Inc.)的Aduhelm，称其药物的定价将具有竞争力。</blockquote> Bill Anderson, head of pharmaceuticals at Roche, did not provide pricing details for the company's treatment for the lethal brain-wasting disease, but indicated in an interview that it could be priced as much as 30% below Aduhelm's $56,000-a-year cost.<blockquote>罗氏制药主管比尔·安德森（Bill Anderson）没有提供该公司治疗致命脑萎缩疾病的定价细节，但在接受采访时表示，其定价可能比Aduhelm每年56,000美元的成本低30%。</blockquote> When it launched in June, Biogen's drug became the first approved medication that targets <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the changes in the brain that occurs with Alzheimer's. But Aduhelm sales have stalled as Medicare, the U.S. government healthcare program for people over age 65, evaluates coverage.<blockquote>当它在6月份上市时，Biogen的药物成为第一个被批准的针对<a href=\"https://laohu8.com/S/AONE.U\">一</a>老年痴呆症患者大脑的变化。但随着美国政府针对65岁以上人群的医疗保健计划Medicare评估承保范围，Aduhelm的销售陷入停滞。</blockquote> The delay has opened up opportunities for rivals such as Roche whose drugs are still many months away from U.S. Food and Drug Administration review and their approval is uncertain.<blockquote>这一延迟为罗氏等竞争对手带来了机会，这些竞争对手的药物距离美国上市还有几个月的时间。食品药品监督管理局的审查和批准是不确定的。</blockquote> Anderson said Roche has priced new therapies in the United States \"at or below the prices of things we replace ... even though we had superior results.\"<blockquote>安德森表示，罗氏在美国对新疗法的定价“等于或低于我们替代产品的价格……尽管我们取得了更好的结果”。</blockquote> Roche, Biogen and other drugmakers are due to present data this week at the annual Clinical Trials on Alzheimer's Disease conference in Boston.<blockquote>罗氏、百健和其他制药商将于本周在波士顿举行的阿尔茨海默病年度临床试验会议上公布数据。</blockquote> Roche's Alzheimer's candidate gantenerumab, like Aduhelm, is designed to remove amyloid plaques from the brains of people diagnosed with the disease. Roche has said it will wait for pivotal trial results, due in the second half of 2022, before seeking regulatory review.<blockquote>罗氏的阿尔茨海默病候选药物gantenerumab与Aduhelm一样，旨在去除被诊断患有该疾病的人大脑中的淀粉样斑块。罗氏表示，将等待2022年下半年的关键试验结果，然后再寻求监管审查。</blockquote> Anderson told Reuters that Roche aims to show \"unequivocal data on efficacy.\"<blockquote>安德森告诉路透社，罗氏的目标是展示“明确的疗效数据”。</blockquote> The FDA approved Biogen's drug based on evidence that it reduces amyloid brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows the disease's progression.<blockquote>FDA批准Biogen的药物是基于它减少淀粉样脑斑块的证据，淀粉样脑斑块可能是阿尔茨海默氏症的一个原因，而不是证明它减缓了疾病的进展。</blockquote> Eli Lilly &amp; Co has begun a rolling FDA application for its own experimental Alzheimer's drug based on evidence of its plaque-removing ability. Lilly's drug could get U.S. approval by the second half of next year.<blockquote>礼来公司(Eli Lilly&amp;Co)已开始向FDA滚动申请其实验性阿尔茨海默病药物，该药物基于其去除斑块能力的证据。礼来公司的药物可能会在明年下半年获得美国批准。</blockquote> Medicare expects to issue a final decision in April on its reimbursement policy, which will apply to all plaque-reducing agents.<blockquote>Medicare预计将在4月份就其报销政策做出最终决定，该政策将适用于所有斑块减少剂。</blockquote> Biogen posted third-quarter Aduhelm sales of just $300,000&nbsp;treatment, far below the $11 million Wall Street had expected. Some neurology centers using the drug have said the company is providing Aduhelm, given as a monthly infusion, free of charge&nbsp;while the insurance claims process is worked out.<blockquote>Biogen公布第三季度Aduhelm治疗销售额仅为30万美元，远低于华尔街预期的1100万美元。一些使用该药物的神经病学中心表示，该公司正在免费提供Aduhelm，每月输注一次，同时制定保险索赔流程。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche executive says Alzheimer's drug price will be competitive<blockquote>罗氏高管表示阿尔茨海默病药物价格将具有竞争力</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche executive says Alzheimer's drug price will be competitive<blockquote>罗氏高管表示阿尔茨海默病药物价格将具有竞争力</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-11-10 19:18\n\n</h4>\n</header>\n<article>\nNov 10 (Reuters) - Roche Holding AG, still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival Biogen Inc's Aduhelm, saying that its medication would be priced competitively.<blockquote>路透11月10日-罗氏控股公司距离其实验性阿尔茨海默病药物获得监管部门批准还有几个月的时间，该公司已经将目标瞄准了竞争对手百健公司(Biogen Inc.)的Aduhelm，称其药物的定价将具有竞争力。</blockquote> Bill Anderson, head of pharmaceuticals at Roche, did not provide pricing details for the company's treatment for the lethal brain-wasting disease, but indicated in an interview that it could be priced as much as 30% below Aduhelm's $56,000-a-year cost.<blockquote>罗氏制药主管比尔·安德森（Bill Anderson）没有提供该公司治疗致命脑萎缩疾病的定价细节，但在接受采访时表示，其定价可能比Aduhelm每年56,000美元的成本低30%。</blockquote> When it launched in June, Biogen's drug became the first approved medication that targets <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the changes in the brain that occurs with Alzheimer's. But Aduhelm sales have stalled as Medicare, the U.S. government healthcare program for people over age 65, evaluates coverage.<blockquote>当它在6月份上市时，Biogen的药物成为第一个被批准的针对<a href=\"https://laohu8.com/S/AONE.U\">一</a>老年痴呆症患者大脑的变化。但随着美国政府针对65岁以上人群的医疗保健计划Medicare评估承保范围，Aduhelm的销售陷入停滞。</blockquote> The delay has opened up opportunities for rivals such as Roche whose drugs are still many months away from U.S. Food and Drug Administration review and their approval is uncertain.<blockquote>这一延迟为罗氏等竞争对手带来了机会，这些竞争对手的药物距离美国上市还有几个月的时间。食品药品监督管理局的审查和批准是不确定的。</blockquote> Anderson said Roche has priced new therapies in the United States \"at or below the prices of things we replace ... even though we had superior results.\"<blockquote>安德森表示，罗氏在美国对新疗法的定价“等于或低于我们替代产品的价格……尽管我们取得了更好的结果”。</blockquote> Roche, Biogen and other drugmakers are due to present data this week at the annual Clinical Trials on Alzheimer's Disease conference in Boston.<blockquote>罗氏、百健和其他制药商将于本周在波士顿举行的阿尔茨海默病年度临床试验会议上公布数据。</blockquote> Roche's Alzheimer's candidate gantenerumab, like Aduhelm, is designed to remove amyloid plaques from the brains of people diagnosed with the disease. Roche has said it will wait for pivotal trial results, due in the second half of 2022, before seeking regulatory review.<blockquote>罗氏的阿尔茨海默病候选药物gantenerumab与Aduhelm一样，旨在去除被诊断患有该疾病的人大脑中的淀粉样斑块。罗氏表示，将等待2022年下半年的关键试验结果，然后再寻求监管审查。</blockquote> Anderson told Reuters that Roche aims to show \"unequivocal data on efficacy.\"<blockquote>安德森告诉路透社，罗氏的目标是展示“明确的疗效数据”。</blockquote> The FDA approved Biogen's drug based on evidence that it reduces amyloid brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows the disease's progression.<blockquote>FDA批准Biogen的药物是基于它减少淀粉样脑斑块的证据，淀粉样脑斑块可能是阿尔茨海默氏症的一个原因，而不是证明它减缓了疾病的进展。</blockquote> Eli Lilly &amp; Co has begun a rolling FDA application for its own experimental Alzheimer's drug based on evidence of its plaque-removing ability. Lilly's drug could get U.S. approval by the second half of next year.<blockquote>礼来公司(Eli Lilly&amp;Co)已开始向FDA滚动申请其实验性阿尔茨海默病药物，该药物基于其去除斑块能力的证据。礼来公司的药物可能会在明年下半年获得美国批准。</blockquote> Medicare expects to issue a final decision in April on its reimbursement policy, which will apply to all plaque-reducing agents.<blockquote>Medicare预计将在4月份就其报销政策做出最终决定，该政策将适用于所有斑块减少剂。</blockquote> Biogen posted third-quarter Aduhelm sales of just $300,000&nbsp;treatment, far below the $11 million Wall Street had expected. Some neurology centers using the drug have said the company is providing Aduhelm, given as a monthly infusion, free of charge&nbsp;while the insurance claims process is worked out.<blockquote>Biogen公布第三季度Aduhelm治疗销售额仅为30万美元，远低于华尔街预期的1100万美元。一些使用该药物的神经病学中心表示，该公司正在免费提供Aduhelm，每月输注一次，同时制定保险索赔流程。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/roche-executive-says-alzheimers-drug-110000076.html\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","LLY":"礼来","RHHBY":"罗氏控股"},"source_url":"https://finance.yahoo.com/news/roche-executive-says-alzheimers-drug-110000076.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121872926","content_text":"Nov 10 (Reuters) - Roche Holding AG, still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival Biogen Inc's Aduhelm, saying that its medication would be priced competitively.\nBill Anderson, head of pharmaceuticals at Roche, did not provide pricing details for the company's treatment for the lethal brain-wasting disease, but indicated in an interview that it could be priced as much as 30% below Aduhelm's $56,000-a-year cost.\nWhen it launched in June, Biogen's drug became the first approved medication that targets one of the changes in the brain that occurs with Alzheimer's. But Aduhelm sales have stalled as Medicare, the U.S. government healthcare program for people over age 65, evaluates coverage.\nThe delay has opened up opportunities for rivals such as Roche whose drugs are still many months away from U.S. Food and Drug Administration review and their approval is uncertain.\nAnderson said Roche has priced new therapies in the United States \"at or below the prices of things we replace ... even though we had superior results.\"\nRoche, Biogen and other drugmakers are due to present data this week at the annual Clinical Trials on Alzheimer's Disease conference in Boston.\nRoche's Alzheimer's candidate gantenerumab, like Aduhelm, is designed to remove amyloid plaques from the brains of people diagnosed with the disease. Roche has said it will wait for pivotal trial results, due in the second half of 2022, before seeking regulatory review.\nAnderson told Reuters that Roche aims to show \"unequivocal data on efficacy.\"\nThe FDA approved Biogen's drug based on evidence that it reduces amyloid brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows the disease's progression.\nEli Lilly & Co has begun a rolling FDA application for its own experimental Alzheimer's drug based on evidence of its plaque-removing ability. Lilly's drug could get U.S. approval by the second half of next year.\nMedicare expects to issue a final decision in April on its reimbursement policy, which will apply to all plaque-reducing agents.\nBiogen posted third-quarter Aduhelm sales of just $300,000 treatment, far below the $11 million Wall Street had expected. Some neurology centers using the drug have said the company is providing Aduhelm, given as a monthly infusion, free of charge while the insurance claims process is worked out.","news_type":1,"symbols_score_info":{"BIIB":0.9,"RHHBY":0.9,"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":303,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/847489142"}